PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-313.81%
Negative net income growth while TRAW stands at 28.72%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
289.12%
SBC growth while TRAW is negative at -73.72%. John Neff would see competitor possibly controlling share issuance more tightly.
-122.10%
Both reduce yoy usage, with TRAW at -290.61%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
113.90%
A yoy AP increase while TRAW is negative at -13800.00%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-180.39%
Both reduce yoy usage, with TRAW at -253.74%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
2618.61%
Some yoy increase while TRAW is negative at -309.68%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
17.02%
Some CFO growth while TRAW is negative at -19.21%. John Neff would note a short-term liquidity lead over the competitor.
-23.76%
Both yoy lines negative, with TRAW at -123.81%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.76%
We reduce yoy invests while TRAW stands at 99.77%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-278.89%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.